Barry Ticho Sells 4,767 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 4,767 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $152,687.01. Following the sale, the insider directly owned 25,655 shares of the company’s stock, valued at approximately $821,729.65. This trade represents a 15.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Barry Ticho also recently made the following trade(s):

• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04.
• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK traded up $0.01 during trading on Tuesday, reaching $32.14. The stock had a trading volume of 574,554 shares, compared to its average volume of 816,472. The company has a market cap of $2.07 billion, a P/E ratio of -9.62 and a beta of 1.20. Stoke Therapeutics, Inc. has a fifty-two week low of $18.00 and a fifty-two week high of $40.22. The business’s 50-day moving average price is $30.81 and its 200-day moving average price is $32.21.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. Analysts forecast that Stoke Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hussman Strategic Advisors Inc. acquired a new stake in Stoke Therapeutics during the fourth quarter worth approximately $2,000,000. Dimensional Fund Advisors LP boosted its holdings in shares of Stoke Therapeutics by 19.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock valued at $32,229,000 after buying an additional 162,797 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Stoke Therapeutics by 11.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock valued at $52,456,000 after buying an additional 161,848 shares in the last quarter. Candriam S.C.A. grew its position in shares of Stoke Therapeutics by 12.4% in the 1st quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock valued at $16,346,000 after buying an additional 55,330 shares during the last quarter. Finally, Granahan Investment Management LLC grew its position in shares of Stoke Therapeutics by 75.3% in the 1st quarter. Granahan Investment Management LLC now owns 335,586 shares of the company’s stock valued at $10,927,000 after buying an additional 144,189 shares during the last quarter.

Wall Street Analyst Weigh In

STOK has been the topic of a number of research reports. Guggenheim reiterated a “buy” rating and set a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price target for the company. Wedbush upped their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Finally, Chardan Capital reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.